Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
Viking Therapeutics closer to bringing its Ozempic competitor to market
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...
BioPharma Dive2d
Viking inks CordenPharma deal to boost obesity drug supply
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...
PharmExec2d
Viking Therapeutics, CordenPharma Strike Multi-Year Deal to Commercialize VK2735 for Obesity, Metabolic Disorders
Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...
Fierce Pharma2d
Viking pays $150M to recruit CordenPharma for obesity drug manufacturing saga
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
BioSpace2d
Viking Secures 1B Supply of Obesity Pill Candidate With $150M Prepayment Deal
Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.
Investing3d
Viking Therapeutics secures supply for obesity drug
Brian Lian, Ph.D., CEO of Viking Therapeutics, expressed confidence in CordenPharma’s ability to meet the anticipated significant commercial demand for VK2735 due to their established presence ...